Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

Italian population-based study reported a more frequent use of ACE inhibitors and ARBs in patients with Covid-19 versus controls because of higher prevalence of cardiovascular disease. However, there was no evidence that ACE inhibitors or ARBs affected the risk of COVID-19.

SPS commentary:

An accompanying editorial discusses the implications of this study and two other related studies, noting that whilst all studies are observational studies with the potential for confounding, none of them demonstrated evidence of harm with continued use of ACE inhibitors and ARBs.


New England Journal of Medicine

Resource links:


Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19